We have attached herewith Investor Presentation as per Regulation 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.

August 05, 2026 To, To, Listing Department, The National Stock Exchange of India BSE Limited Ltd. Phiroze Jeejeebhoy Towers, The Listing Department Dalal Street, Exchange Plaza, Mumbai – 400 001 Bandra – Kurla Complex, Ref: BSE Scrip Code: 544497 Mumbai – 400051, NSE Scrip Code: AHCL Subject: Investor Presentation – Q1 & FY - 27 Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the investor presentation for Q1 & FY - 27 for the Financial Year 2026-2027, which is uploaded on our website as well. The same can be accessed through the link below: https://www.anlon.in/reports.php?subid=15&name=Investor-Meet. You are requested to take the above information on your record. Thanking You. Yours Faithfully, For ANLON HEALTHCARE LIMITED PUNITKUMAR RASADIA MANAGING DIRECTOR DIN: 06696258 ANLON HEALTHCARE LIMITED CIN No.: L24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in Anlon Healthcare Ltd. Investor Presentation About Us Incorporated in 2013 and based in Rajkot, Gujarat, Anlon Healthcare Ltd. is a research-driven chemical manufacturer Engaged in manufacturing high-purity advanced pharmaceutical intermediates, used as key starting materials for APIs and active pharmaceutical ingredients (APIs), which serve as raw materials for finished dosage formulations Among the few Indian manufacturers of Loxoprofen Sodium Dihydrate, Ketoprofen & Dexketoprofen Trometamol a key APIs used for pain and inflammation. Strong global presence across 15 countries, serving pharmaceutical, nutraceutical, personal care, and animal health sectors INVESTOR PRESENTATION 2 Transformational Acquisitions Powering Next Phase of Growth Capacity Expansion Through Acquisition: Inorganic Growth: Acquisition of Apiqo Bizotic Lifescience Pvt. Ltd. Organics Pvt. Ltd. • Transaction Snapshot • Transaction Snapshot Stake: 67.48% | Consideration: ₹5.40 crore (cash) Stake: 56.67% | Consideration: ₹3.79 crore (cash) Shares: 55.34 lakh | Price: ₹9.76 per share Shares: 25.50 lakh | Price: ₹14.89 per share Status: Acquisition Completed Status: SPA executed; completion expected within ~3 Apiqo is a subsidiary of Anlon Healthcare Limited months Bizotic has become a subsidiary of Anlon Healthcare • Strategic Rationale Strengthens backward integration for critical pharmaceutical Limited intermediates & Industrial & Fine Chemicals Provides a ready, established manufacturing platform with • Strategic Rationale faster scalability Ready-to-operate manufacturing facility, reducing Improves cost competitiveness, supply security, and greenfield execution risk and timelines operational agility Accelerates capacity expansion and strengthens regulatory readiness • Capacity & Growth Impact Enhances service capability across domestic API markets Incremental capacity: 700–800 MTPA (Apiqo) Existing Anlon capacity: 400 MTPA Bizotic acquisition: additional 300–400 MTPA • Value Creation Outlook Total projected capacity: 1,400–1,600 MTPA by FY26 Strong fit with Anlon’s R&D pipeline and 21 global DMF filings • Value Creation Outlook Supports Anlon’s guidance of ~30% revenue CAGR over Supports margin sustainability through raw-material integration next 3 years Positions Anlon for scalable and resilient long-term growth INVESTOR PRESENTATION 3 Strengthening Our Position as an Integrated Pharmaceutical Company Transaction Overview Acquired Company 01 Remember India Health Links Pvt. Ltd. Stake Acquired 02 63.98% Acquisition Value 03 ₹5.38 Crore Shares Acquired 04 1.11 Crore Equity Shares Completion Date 05 8 May 2026 Remember India Health Links became a Subsidiary of Result 06 Anlon Healthcare Ltd. About Remember India Health Links Pvt. Ltd. Strategic Rationale •Incorporated in December 2020 Expand Across the Pharmaceutical Value Chain •Transition from an API-focused manufacturer to an integrated •Engaged in manufacturing and marketing of finished pharmaceutical formulations pharmaceutical company •Entry into Finished Dosage Formulations (FDFs) •Products include tablets, capsules and other pharmaceutical formulations •FY25 Turnover: ₹83.08 Lakhs Broaden Product Portfolio Stronger Market Position Operational Synergies •Presence across B2B APIs, domestic retail and •Integration of manufacturing and quality control •Access to 30+ formulation dossiers hospital markets processes •Strengthens capabilities in tablets, •Creates a broader pharmaceutical & healthcare •Enhanced operational efficiencies capsules and pharmaceutical formulations platform •Stronger financial profile and long-term scalability INVESTOR PRESENTATION 4 Key Performance Metrics Global Presence: Regulatory Strength: Diverse Portfolio: Customer Base: Operations across 15 21 Drug Master Files filed 65 commercialized Served 125 customers countries with global authorities products, 28 in pilot stage, till date (directly & and 49 under lab testing Indirectly) Workforce Industry Manufacturing Strength: Experience: Capacity: Over 7 years in 1,400-1,600 MTPA 105 employees manufacturing and sale installed production across operations of Pharma capacity Intermediates & APIs INVESTOR PRESENTATION 5 Regulatory Filings ❖ As on date, we have received approval for Drug Master File from and In process for Approval from the following CEP Approval from EDQM (Europe) for our APIs product namely, Ketoprofen Brazilian Health Regulatory Agency (“ANVISA, Brazil”) for our APIs product namely, loxoprofen sodium dihydrate. CEP,Europe National Medical Products Administration,China National Medical Products Administration, China (“NMPA, China”) for our APIs product namely, loxoprofen sodium dihydrate. The Company has filed 21 DMFs with regulators across major international markets and is progressing DMF submissions for Ketoprofen in the USA and Brazil, Health Dexketoprofen Trometamol in key European jurisdictions. The Approval is Regulatory Agency,ANVISA expected in a couple of years INVESTOR PRESENTATION 6 Advancing Health with Purpose and Vision MISSION With an approach to innovation that is compelling, inclusive and visionary, we seek to drive efficiency and productivity while delivering tangible results. To harness the strength of technology and research into becoming a leading global pharmaceutical company that delivers maximum consumer satisfaction. VISION INVESTOR PRESENTATION 7 Building a Legacy of Growth Commenced commercial production of Pharma Intermediates and APIs • Exported first batch to South Korea • Received GMP certification from FDCA, Incorporated as Anlon Received WHO- Gujarat Ventures Private GMP certification Got listed on • Obtained Foreign Manufacturer Accreditation Limited for manufacturing BSE & NSE from PMDA, Japan facility 2013 2018 2021 2025 2026 2015 2019 2024 Achieved ISO Acquired Apiqo Organics Renamed to Received Drug Master File 9001:2015 Pvt. Ltd. ,Bizotic Anlon Healthcare (DMF) Certification Lifescience Pvt. Ltd. & Private Limited Approval from Brazilian Health Remember India Health Regulatory Agency for Loxoprofen Links Pvt Ltd. ; which Sodium Dihydrate became subsidiaries of Converted to a public limited company and renamed Anlon Anlon Healthcare Healthcare Limited Limited. INVESTOR PRESENTATION 8 Manufacturing & Capacity Platform • 1,400-1,600 MTPA installed capacity (current) • Capacity utilization: 62.37% • Two dedicated blocks – APIs & Intermediates • Glass-lined & SS reactors with scale-up capability (20L–200L assemblies) • Strategic location: Rajkot (NH-27 connectivity) INVESTOR PRESENTATION 9 R&D & Custom Manufacturing Engine •Dedicated R&D labs | 11 fume cupboards •Experienced R&D team •End-to-end CDMO capability (Process dev → Commercial production) •Focused on high-value NSAIDs & specialty APIs INVESTOR PRESENTATION 10 Business Overview 1/2 Active Pharma [Showing first 8,000 characters — download PDF for full document]